News stories about Neurocrine Biosciences (NASDAQ:NBIX) have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Neurocrine Biosciences earned a news sentiment score of 0.15 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 45.9604646665802 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Here are some of the headlines that may have impacted Accern Sentiment Analysis’s analysis:
- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) – Active Stock Evaluation – Nasdaq Journal (press release) (nasdaqjournal.com)
- Neurocrine, Ingrezza Sail Into 2018 – Seeking Alpha (seekingalpha.com)
- FY2017 EPS Estimates for Neurocrine Biosciences, Inc. Increased by Leerink Swann (NBIX) (americanbankingnews.com)
- 10 Top Penny Stocks to Watch This Week for Under $2 (moneymorning.com)
- CELG Makes Blockbuster Purchase, MDXG, NBIX On Watch, Busy Year Ahead For ALNY – Nasdaq (nasdaq.com)
Several analysts have issued reports on NBIX shares. Needham & Company LLC reissued a “buy” rating and issued a $86.00 price target on shares of Neurocrine Biosciences in a research note on Thursday, November 2nd. Citigroup reissued a “buy” rating and issued a $79.00 price target on shares of Neurocrine Biosciences in a research note on Thursday, November 2nd. Piper Jaffray Companies reissued a “buy” rating and issued a $76.00 price target on shares of Neurocrine Biosciences in a research note on Wednesday, October 25th. Jefferies Group reissued a “buy” rating and issued a $69.00 price target (up previously from $66.00) on shares of Neurocrine Biosciences in a research note on Tuesday, October 3rd. Finally, Deutsche Bank reissued a “buy” rating and issued a $79.00 price target on shares of Neurocrine Biosciences in a research note on Thursday, November 2nd. One equities research analyst has rated the stock with a hold rating and eighteen have assigned a buy rating to the company. Neurocrine Biosciences presently has an average rating of “Buy” and a consensus target price of $81.13.
Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings data on Wednesday, November 1st. The company reported ($0.13) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.49) by $0.36. The company had revenue of $60.77 million during the quarter, compared to the consensus estimate of $29.38 million. During the same quarter in the previous year, the business earned ($0.43) EPS. sell-side analysts anticipate that Neurocrine Biosciences will post -1.66 earnings per share for the current fiscal year.
In related news, Director Gary A. Lyons sold 10,000 shares of Neurocrine Biosciences stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $72.92, for a total transaction of $729,200.00. Following the completion of the transaction, the director now owns 272,066 shares in the company, valued at $19,839,052.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Darin Lippoldt sold 1,979 shares of Neurocrine Biosciences stock in a transaction dated Wednesday, January 3rd. The stock was sold at an average price of $79.36, for a total value of $157,053.44. The disclosure for this sale can be found here. Insiders sold a total of 116,405 shares of company stock valued at $8,588,519 in the last 90 days. 4.80% of the stock is owned by corporate insiders.
ILLEGAL ACTIVITY WARNING: This news story was first reported by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this news story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://stocknewstimes.com/2018/01/12/neurocrine-biosciences-nbix-getting-somewhat-favorable-news-coverage-report-finds.html.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.